Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma.
Saved in:
| Title: | Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma. |
|---|---|
| Authors: | Hou X; Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA., Zanfagnin V; Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA., Xu C; Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA.; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mayo Clinic, MN, 55905, USA., Jessen E; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA., Liu Y; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA., Wang C; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.; Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, 55905, USA., Huang Y; Division of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA., Fontaine SD; ProLynx LLC, 455 Mission Bay Blvd, South San Francisco, CA, 94158, USA., Santi DV; ProLynx LLC, 455 Mission Bay Blvd, South San Francisco, CA, 94158, USA., Colon-Otero G; Hematology/Oncology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA., Gill SE; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mayo Clinic, MN, 55905, USA., Glaser GE; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mayo Clinic, MN, 55905, USA., Butler KA; Medical & Surgical Gynecology Department, Mayo Clinic, Phoenix, AZ, USA., Bakkum-Gamez JN; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mayo Clinic, MN, 55905, USA., Dowdy SC; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mayo Clinic, MN, 55905, USA., Oberg AL; Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, MN, 55905, USA., Larson MC; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, 55905, USA., Atkinson HJ; Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, 55905, USA., Duffield LN; Division of Oncology Research, Mayo Clinic, Rochester, MN, 55905, USA., Peterson KL; Division of Oncology Research, Mayo Clinic, Rochester, MN, 55905, USA., Kaufmann SH; Division of Oncology Research, Mayo Clinic, Rochester, MN, 55905, USA.; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA., Weroha SJ; Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA. Weroha.Saravut@mayo.edu.; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA. Weroha.Saravut@mayo.edu.; Department of Oncology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN, 55905, USA. Weroha.Saravut@mayo.edu. |
| Source: | Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2025 May 19; Vol. 44 (1), pp. 150. Date of Electronic Publication: 2025 May 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966 (Electronic) Linking ISSN: 03929078 NLM ISO Abbreviation: J Exp Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
